Supplementary tables: Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Systematic review of outcomes and patient </b><b>heterogeneity in relapsed or refractory </b><b>diffuse large B-cell lymphoma</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Supplementary Table 1:</b> PICOS criteria defining the scope of the current SLR</li><li><b>Supplementary Table 2: </b>Search strategies</li><li><b>Supplementary table 3:</b> MINORS assessments</li><li><b>Supplementary table 4: </b>Cochrane Risk of Bias 2 assessments</li></ul><p dir="ltr"><b>Aim:</b> To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). <b>Patients & methods: </b>Systematically reviewed multiple databases through 22 July 2021. Analyzed variations in patient characteristics and their relationship with ORR across trials. <b>Results:</b> Among 17 included trials, key patient characteristics varied substantially: primary refractory (0–69%), refractory to last line of therapy (LOT) (12–100%), ≥2 prior LOTs (14–100%), ≥3 prior LOTs (0–64%), IPI ≥3 (23–73%), tumor stage III/IV (50–90%) and median age (56–74 years). ORRs varied substantially (25–83%), correlating with these characteristics. <b>Conclusion:</b> Differences in patient characteristics significantly contribute to the variability in ORR across these trials and should be considered when contextualizing efficacy data.</p>